State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan
Abstract
:1. Characteristics of Lung Cancer Patients in Taiwan
2. Molecular Epidemiology and Pathophysiology of Lung Cancer in Taiwan
3. Translational Oncology Studies of Lung Cancer in Taiwan
3.1. EGFR
3.2. ALK
3.3. Rare Mutation Other Than EGFR and ALK
3.4. Small Cell Lung Cancer
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Luo, Y.H.; Chiu, C.H.; Scott Kuo, C.H.; Chou, T.Y.; Yeh, Y.C.; Hsu, H.S.; Yen, S.H.; Wu, Y.H.; Yang, J.C.; Liao, B.C.; et al. Lung Cancer in Republic of China. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2021, 16, 519–527. [Google Scholar] [CrossRef]
- Health Promotion Administration; Ministry of Health and Welfare. Taiwan. 2019 Cancer Registry Annual Report. Available online: https://www.hpa.gov.tw/Pages/ashx/File.ashx?FilePath=~/File/Attach/14913/File_17794.pdf (accessed on 4 February 2022).
- Chen, Y.-J.; Roumeliotis, T.I.; Chang, Y.-H.; Chen, C.-T.; Han, C.-L.; Lin, M.-H.; Chen, H.-W.; Chang, G.-C.; Chang, Y.-L.; Wu, C.-T.; et al. Proteogenomics of non-smoking lung cancer in east asia delineates molecular signatures of pathogenesis and progression. Cell 2020, 182, 226–244.e217. [Google Scholar] [CrossRef]
- Gillette, M.A.; Satpathy, S.; Cao, S.; Dhanasekaran, S.M.; Vasaikar, S.V.; Krug, K.; Petralia, F.; Li, Y.; Liang, W.W.; Reva, B.; et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell 2020, 182, 200–225.e235. [Google Scholar] [CrossRef]
- Liang, K.-H.; Wang, M.-L. Deep proteogenomic investigations elucidate the NRF2 antioxidant mechanism as a major driving mechanism of lung adenocarcinoma in Asia. J. Chin. Med. Assoc. 2021, 84, 766–771. [Google Scholar] [CrossRef]
- Wang, B.; Mezlini, A.M.; Demir, F.; Fiume, M.; Tu, Z.; Brudno, M.; Haibe-Kains, B.; Goldenberg, A. Similarity network fusion for aggregating data types on a genomic scale. Nat. Methods 2014, 11, 333–337. [Google Scholar] [CrossRef]
- Chang, H.Y.; Sneddon, J.B.; Alizadeh, A.A.; Sood, R.; West, R.B.; Montgomery, K.; Chi, J.-T.; van de Rijn, M.; Botstein, D.; Brown, P.O. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol. 2004, 2, E7. [Google Scholar] [CrossRef] [Green Version]
- Cahoy, J.D.; Emery, B.; Kaushal, A.; Foo, L.C.; Zamanian, J.L.; Christopherson, K.S.; Xing, Y.; Lubischer, J.L.; Krieg, P.A.; Krupenko, S.A.; et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. J. Neurosci. 2008, 28, 264–278. [Google Scholar] [CrossRef] [Green Version]
- Ramírez-Valle, F.; Braunstein, S.; Zavadil, J.; Formenti, S.C.; Schneider, R.J. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J. Cell Biol. 2008, 181, 293–307. [Google Scholar] [CrossRef] [Green Version]
- Bild, A.H.; Yao, G.; Chang, J.T.; Wang, Q.; Potti, A.; Chasse, D.; Joshi, M.-B.; Harpole, D.; Lancaster, J.M.; Berchuck, A.; et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2005, 439, 353–357. [Google Scholar] [CrossRef]
- Arima, C.; Kajino, T.; Tamada, Y.; Imoto, S.; Shimada, Y.; Nakatochi, M.; Suzuki, M.; Isomura, H.; Yatabe, Y.; Yamaguchi, T.; et al. Lung adenocarcinoma subtypes definable by lung development-related miRNA expression profiles in association with clinicopathologic features. Carcinogenesis 2014, 35, 2224–2231. [Google Scholar] [CrossRef]
- Xu, F.; Chen, J.-X.; Yang, X.-B.; Hong, X.-B.; Li, Z.-X.; Lin, L.; Chen, Y.-S. Analysis of Lung Adenocarcinoma Subtypes Based on Immune Signatures Identifies Clinical Implications for Cancer Therapy. Mol. Ther. Oncolytics 2020, 17, 241–249. [Google Scholar] [CrossRef]
- Huang, S.F.; Liu, H.P.; Li, L.H.; Ku, Y.C.; Fu, Y.N.; Tsai, H.Y.; Chen, Y.T.; Lin, Y.F.; Chang, W.C.; Kuo, H.P.; et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004, 10, 8195–8203. [Google Scholar] [CrossRef] [Green Version]
- Hsu, K.H.; Ho, C.C.; Hsia, T.C.; Tseng, J.S.; Su, K.Y.; Wu, M.F.; Chiu, K.L.; Yang, T.Y.; Chen, K.C.; Ooi, H.; et al. Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. PLoS ONE 2015, 10, e0120852. [Google Scholar] [CrossRef] [Green Version]
- Wu, S.G.; Chang, Y.L.; Yu, C.J.; Yang, P.C.; Shih, J.Y. Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res. 2017, 3, 00092–2016. [Google Scholar] [CrossRef] [Green Version]
- Hsu, C.H.; Tseng, C.H.; Chiang, C.J.; Hsu, K.H.; Tseng, J.S.; Chen, K.C.; Wang, C.L.; Chen, C.Y.; Yen, S.H.; Chiu, C.H.; et al. Characteristics of young lung cancer: Analysis of Taiwan’s nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget 2016, 7, 46628–46635. [Google Scholar] [CrossRef] [Green Version]
- Tseng, C.H.; Chiang, C.J.; Tseng, J.S.; Yang, T.Y.; Hsu, K.H.; Chen, K.C.; Wang, C.L.; Chen, C.Y.; Yen, S.H.; Tsai, C.M.; et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget 2017, 8, 98384–98393. [Google Scholar] [CrossRef] [Green Version]
- He, C.H.; Shih, J.F.; Lai, S.L.; Chen, Y.M. Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder. J. Chin. Med. Assoc. 2020, 83, 461–465. [Google Scholar] [CrossRef]
- Luo, Y.-H.; Tseng, P.-C.; Lee, Y.-C.; Perng, R.-P.; Whang-Peng, J.; Chen, Y.-M. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma. Cancer Biomark. Sect. A Dis. Markers 2015, 16, 19–29. [Google Scholar] [CrossRef]
- Luo, Y.H.; Ho, H.L.; Tsai, C.M.; Shih, J.F.; Chiu, C.H.; Lai, S.L.; Lee, Y.C.; Perng, R.P.; Whang-Peng, J.; Chou, T.Y.; et al. The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs. Am. J. Clin. Oncol. 2015, 38, 147–151. [Google Scholar] [CrossRef]
- Luo, Y.H.; Wu, C.H.; Wu, W.S.; Huang, C.Y.; Su, W.J.; Tsai, C.M.; Lee, Y.C.; Perng, R.P.; Chen, Y.M. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2012, 7, 299–305. [Google Scholar] [CrossRef] [Green Version]
- Mok, T.S.; Wu, Y.L.; Thongprasert, S.; Yang, C.H.; Chu, D.T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361, 947–957. [Google Scholar] [CrossRef] [PubMed]
- Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353, 123–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, J.C.; Wu, Y.L.; Schuler, M.; Sebastian, M.; Popat, S.; Yamamoto, N.; Zhou, C.; Hu, C.P.; O’Byrne, K.; Feng, J.; et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015, 16, 141–151. [Google Scholar] [CrossRef] [Green Version]
- Wu, Y.L.; Cheng, Y.; Zhou, X.; Lee, K.H.; Nakagawa, K.; Niho, S.; Tsuji, F.; Linke, R.; Rosell, R.; Corral, J.; et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 2017, 18, 1454–1466. [Google Scholar] [CrossRef]
- Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T.; et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 113–125. [Google Scholar] [CrossRef]
- Chen, Y.M. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. J. Chin. Med. Assoc. 2013, 76, 249–257. [Google Scholar] [CrossRef] [Green Version]
- Chung, C.H. EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan. Oncol. Lett. 2019, 18, 6090–6100. [Google Scholar] [CrossRef]
- Chen, Y.M. Epidermal growth factor receptor mutation in adenosquamous carcinoma: A step forward. J. Chin. Med. Assoc. 2013, 76, 477–478. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.Y.; Lin, H.F.; Lai, W.Y.; Lin, Y.Y.; Lin, T.W.; Yang, Y.P.; Tsai, F.T.; Wang, C.L.; Luo, Y.H.; Chen, Y.M.; et al. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers. J. Chin. Med. Assoc. 2022, 85, 409–413. [Google Scholar] [CrossRef]
- Hsu, C.C.; Huang, Y.T.; Tseng, Y.H.; Luo, Y.H.; Chen, Y.M. Prognostic factors and first-line treatment modalities in nonagenarian patients with lung cancer. J. Geriatr. Oncol. 2019, 10, 439–441. [Google Scholar] [CrossRef]
- Wu, S.G.; Yu, C.J.; Yang, J.C.; Shih, J.Y. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther. Adv. Med. Oncol. 2020, 12, 1758835920946156. [Google Scholar] [CrossRef] [PubMed]
- Chen, P.Y.; Wang, C.C.; Hsu, C.N.; Chen, C.Y. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Front. Pharmacol. 2021, 12, 720687. [Google Scholar] [CrossRef] [PubMed]
- Su, V.Y.; Yang, K.Y.; Huang, T.Y.; Hsu, C.C.; Chen, Y.M.; Yen, J.C.; Chou, Y.C.; Chang, Y.L.; He, C.H. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. Sci. Rep. 2020, 10, 14965. [Google Scholar] [CrossRef] [PubMed]
- Hung, H.Y.; Tseng, Y.H.; Liao, C.M.; Chen, S.Y.; Wu, T.P.; Lee, Y.C.; Chen, Y.M. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment. Integr. Cancer Ther. 2017, 16, 126–131. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huang, Y.H.; Hsu, K.H.; Chin, C.S.; Tseng, J.S.; Yang, T.Y.; Chen, K.C.; Su, K.Y.; Yu, S.L.; Chen, J.J.W.; Chang, G.C. The Clinical Outcomes of Different First-Line EGFR-TKIs plus Bevacizumab in Advanced EGFR-mutant Lung Adenocarcinoma. Cancer Res. Treat. 2021, 54, 434–444. [Google Scholar] [CrossRef]
- Hsu, P.C.; Huang, C.Y.; Wang, C.C.; Kuo, S.C.; Chu, C.H.; Tung, P.H.; Huang, A.C.; Wang, C.L.; Chiu, L.C.; Fang, Y.F.; et al. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals 2020, 13, 331. [Google Scholar] [CrossRef]
- Kuo, C.S.; Chiu, T.H.; Tung, P.H.; Huang, C.H.; Ju, J.S.; Huang, A.C.; Wang, C.C.; Ko, H.W.; Hsu, P.C.; Fang, Y.F.; et al. Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. Cancers 2022, 14, 316. [Google Scholar] [CrossRef]
- Shen, C.I.; Chao, H.S.; Shiao, T.H.; Chiang, C.L.; Huang, H.C.; Luo, Y.H.; Chiu, C.H.; Chen, Y.M. Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Sci. Rep. 2021, 11, 16122. [Google Scholar] [CrossRef]
- Jiang, L.; Liu, J. Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer. Oncol. Lett. 2022, 23, 165. [Google Scholar] [CrossRef]
- Kawana, S.; Saito, R.; Miki, Y.; Kimura, Y.; Abe, J.; Sato, I.; Endo, M.; Sugawara, S.; Sasano, H. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Med. 2021, 10, 718–727. [Google Scholar] [CrossRef]
- Tseng, Y.H.; Hung, H.Y.; Sung, Y.C.; Tseng, Y.C.; Lee, Y.C.; Whang-Peng, J.; Chen, Y.M. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). J. Chemother. 2016, 28, 50–58. [Google Scholar] [CrossRef] [PubMed]
- Tseng, Y.H.; Tseng, Y.C.; Lin, Y.H.; Lee, Y.C.; Perng, R.P.; Whang-Peng, J.; Chen, Y.M. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients. Oncologist 2015, 20, 758–766. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chang, G.C.; Tseng, C.H.; Hsu, K.H.; Yu, C.J.; Yang, C.T.; Chen, K.C.; Yang, T.Y.; Tseng, J.S.; Liu, C.Y.; Liao, W.Y.; et al. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer–A multicenter retrospective SEQUENCE study. Lung Cancer 2017, 104, 58–64. [Google Scholar] [CrossRef]
- Wu, W.S.; Wu, C.H.; Lai, S.L.; Chiu, C.H.; Shih, J.F.; Lee, Y.C.; Chen, Y.M. Erlotinib Salvage Therapy in Pulmonary Adenocarcinoma Patients With Disease Progression After Previous EGFR-TKI Treatment. Am. J. Clin. Oncol. 2016, 39, 556–562. [Google Scholar] [CrossRef]
- Wu, W.S.; Chen, Y.M. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J. Pers. Med. 2014, 4, 297–310. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Luo, Y.H.; Chen, Y.M. Influence of chemotherapy on EGFR mutation status. Transl. Lung Cancer Res. 2013, 2, 442–444. [Google Scholar] [CrossRef]
- Tseng, S.E.; Chiou, Y.Y.; Lee, Y.C.; Perng, R.P.; Jacqueline, W.P.; Chen, Y.M. Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases. Lung Cancer 2014, 86, 225–230. [Google Scholar] [CrossRef]
- Luo, Y.H.; Liu, H.; Wampfler, J.A.; Tazelaar, H.D.; Li, Y.; Peikert, T.; Liu, D.; Leventakos, K.; Chen, Y.M.; Yang, Y.; et al. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. J. Cancer Res. Clin. Oncol. 2021. [Google Scholar] [CrossRef]
- Wu, S.G.; Chiang, C.L.; Liu, C.Y.; Wang, C.C.; Su, P.L.; Hsia, T.C.; Shih, J.Y.; Chang, G.C. An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. Front. Oncol. 2020, 10, 1481. [Google Scholar] [CrossRef]
- Tseng, J.S.; Su, K.Y.; Yang, T.Y.; Chen, K.C.; Hsu, K.H.; Chen, H.Y.; Tsai, C.R.; Yu, S.L.; Chang, G.C. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: Focus on rebiopsy timing and long-term existence of T790M. Oncotarget 2016, 7, 48059–48069. [Google Scholar] [CrossRef] [Green Version]
- Chiang, C.L.; Huang, H.C.; Shen, C.I.; Luo, Y.H.; Chen, Y.M.; Chiu, C.H. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. Target. Oncol. 2020, 15, 503–512. [Google Scholar] [CrossRef] [PubMed]
- Huang, Y.H.; Hsu, K.H.; Tseng, J.S.; Chen, K.C.; Hsu, C.H.; Su, K.Y.; Chen, J.J.W.; Chen, H.W.; Yu, S.L.; Yang, T.Y.; et al. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma. Cancer Res. Treat. 2018, 50, 1294–1303. [Google Scholar] [CrossRef] [Green Version]
- Cheng, W.C.; Hsia, T.C.; Tu, C.Y.; Chen, H.J. The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy. OncoTargets Ther. 2020, 13, 13425–13435. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.T.; Chen, J.S.; Liao, W.Y.; Ho, C.C.; Hsu, C.L.; Yang, C.Y.; Chen, K.Y.; Lee, J.H.; Lin, Z.Z.; Shih, J.Y.; et al. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int. J. Cancer J. Int. Du Cancer 2019, 144, 2887–2896. [Google Scholar] [CrossRef]
- Lin, Y.T.; Tsai, T.H.; Wu, S.G.; Liu, Y.N.; Yu, C.J.; Shih, J.Y. Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer. Lung Cancer 2020, 145, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Lin, C.C.; Shih, J.Y.; Yu, C.J.; Ho, C.C.; Liao, W.Y.; Lee, J.H.; Tsai, T.H.; Su, K.Y.; Hsieh, M.S.; Chang, Y.L.; et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: A genomic study. Lancet Respir. Med. 2018, 6, 107–116. [Google Scholar] [CrossRef]
- Ho, C.C.; Liao, W.Y.; Lin, C.A.; Shih, J.Y.; Yu, C.J.; Yang, J.C. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2017, 12, 567–572. [Google Scholar] [CrossRef] [Green Version]
- Su, P.L.; Tsai, J.S.; Yang, S.C.; Wu, Y.L.; Tseng, Y.L.; Chang, C.C.; Yen, Y.T.; Lin, C.Y.; Lin, C.C.; Wang, C.C.; et al. Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment. Lung Cancer 2021, 158, 137–145. [Google Scholar] [CrossRef]
- Luo, Y.H.; Wu, C.H.; Huang, C.Y.; Wu, C.W.; Wu, W.S.; Lee, Y.C.; Whang-Peng, J.; Chen, Y.M. Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung. Asia Pac. J. Clin. Oncol. 2017, 13, e440–e448. [Google Scholar] [CrossRef]
- Shen, C.I.; Huang, H.C.; Chiang, C.L.; Luo, Y.H.; Shiao, T.H.; Chiu, C.H. Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. Lung Cancer 2019, 138, 52–57. [Google Scholar] [CrossRef]
- Wu, W.S.; Chen, Y.M.; Tsai, C.M.; Shih, J.F.; Lee, Y.C.; Perng, R.P.; Whang-Peng, J. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer. J. Chin. Med. Assoc. 2013, 76, 682–685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chiou, G.Y.; Chiang, C.L.; Yang, H.C.; Shen, C.I.; Wu, H.M.; Chen, Y.W.; Chen, C.J.; Luo, Y.H.; Hu, Y.S.; Lin, C.J.; et al. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. J. Neurosurg. 2021, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.C.; Hsu, S.P.C.; Lin, C.J.; Wu, H.M.; Chen, Y.W.; Luo, Y.H.; Chiang, C.L.; Hu, Y.S.; Chung, W.Y.; Shiau, C.Y.; et al. Epidermal growth factor receptor mutations: Association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases. J. Neurosurg. 2019, 133, 313–320. [Google Scholar] [CrossRef] [PubMed]
- Chiang, C.L.; Lee, C.C.; Huang, H.C.; Wu, C.H.; Yeh, Y.C.; Shen, C.I.; Luo, Y.H.; Shiao, T.H.; Chang, H.J.; Huang, Y.T.; et al. Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. Target. Oncol. 2021, 16, 207–214. [Google Scholar] [CrossRef] [PubMed]
- Chiang, C.L.; Huang, H.C.; Luo, Y.H.; Chiu, C.H. Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis. Front. Biosci. 2021, 26, 1679–1688. [Google Scholar] [CrossRef]
- Su, Y.H.; Chiang, C.L.; Yang, H.C.; Hu, Y.S.; Chen, Y.W.; Luo, Y.H.; Chen, C.J.; Wu, H.M.; Lin, C.J.; Lee, C.C. Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis. Acta Neurochir. 2022, 164, 459–467. [Google Scholar] [CrossRef]
- Su, P.L.; Chang, G.C.; Hsiao, S.H.; Hsia, T.C.; Lin, M.C.; Lin, M.H.; Shih, J.Y.; Yang, C.T.; Yang, S.H.; Chen, Y.M. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study. JTO Clin. Res. Rep. 2022, 3, 100292. [Google Scholar] [CrossRef]
- Wang, S.Y.; Lai, C.H.; Chen, C.W.; Yang, S.C.; Chang, C.C.; Lin, C.Y.; Yen, Y.T.; Tseng, Y.L.; Su, P.L.; Lin, C.C.; et al. Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors. Thorac. Cancer 2022, 13, 182–189. [Google Scholar] [CrossRef]
- Hsu, S.C.; Hung, T.H.; Wang, C.W.; Ng, K.F.; Chen, T.C. Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer. Pathol. Int. 2015, 65, 231–239. [Google Scholar] [CrossRef]
- Chang, G.C.; Yang, T.Y.; Chen, K.C.; Hsu, K.H.; Huang, Y.H.; Su, K.Y.; Yu, S.L.; Tseng, J.S. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. Sci. Rep. 2020, 10, 21063. [Google Scholar] [CrossRef]
- Yang, C.Y.; Liao, W.Y.; Ho, C.C.; Chen, K.Y.; Tsai, T.H.; Hsu, C.L.; Liu, Y.N.; Su, K.Y.; Chang, Y.L.; Wu, C.T.; et al. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist 2020, 25, 702–711. [Google Scholar] [CrossRef] [PubMed]
- Shaw, A.T.; Yeap, B.Y.; Mino-Kenudson, M.; Digumarthy, S.R.; Costa, D.B.; Heist, R.S.; Solomon, B.; Stubbs, H.; Admane, S.; McDermott, U.; et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009, 27, 4247–4253. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, P.; Kulig, K.; Boland, J.M.; Erickson-Johnson, M.R.; Oliveira, A.M.; Wampfler, J.; Jatoi, A.; Deschamps, C.; Marks, R.; Fortner, C.; et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2012, 7, 90–97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gainor, J.F.; Shaw, A.T.; Sequist, L.V.; Fu, X.; Azzoli, C.G.; Piotrowska, Z.; Huynh, T.G.; Zhao, L.; Fulton, L.; Schultz, K.R.; et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016, 22, 4585–4593. [Google Scholar] [CrossRef] [Green Version]
- Wang, C.C.; Huang, K.T.; Chang, H.C.; Tseng, C.C.; Lai, C.H.; Lan, J.; Liu, T.T.; Huang, C.C.; Lin, M.C. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac. Cancer 2022, 13, 38–47. [Google Scholar] [CrossRef]
- Lin, Y.T.; Liu, Y.N.; Shih, J.Y. The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4-ALK Rearranged Non-small Cell Lung Cancer. Front. Oncol. 2019, 9, 880. [Google Scholar] [CrossRef]
- Lin, Y.T.; Chiang, C.L.; Hung, J.Y.; Lee, M.H.; Su, W.C.; Wu, S.Y.; Wei, Y.F.; Lee, K.Y.; Tseng, Y.H.; Su, J.; et al. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: A multicenter study using targeted next-generation sequencing. Eur. J. Cancer 2021, 156, 1–11. [Google Scholar] [CrossRef]
- Lin, Y.T.; Yu, C.J.; Yang, J.C.; Shih, J.Y. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin. Lung Cancer 2016, 17, e77–e94. [Google Scholar] [CrossRef]
- Huang, S.H.; Huang, A.C.; Wang, C.C.; Chang, W.C.; Liu, C.Y.; Pavlidis, S.; Ko, H.W.; Chung, F.T.; Hsu, P.C.; Guo, Y.K.; et al. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thorac. Cancer 2019, 10, 2274–2281. [Google Scholar] [CrossRef]
- Kuo, C.S.; Tung, P.H.; Huang, A.C.; Wang, C.C.; Chang, J.W.; Liu, C.Y.; Chung, F.T.; Fang, Y.F.; Guo, Y.K.; Yang, C.T. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. BMC Cancer 2021, 21, 309. [Google Scholar] [CrossRef]
- Gow, C.H.; Hsieh, M.S.; Wu, S.G.; Shih, J.Y. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung Cancer 2017, 103, 82–89. [Google Scholar] [CrossRef] [PubMed]
- Chang, Y.S.; Tu, S.J.; Chen, Y.C.; Liu, T.Y.; Lee, Y.T.; Yen, J.C.; Fang, H.Y.; Chang, J.G. Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir. Res. 2021, 22, 3. [Google Scholar] [CrossRef] [PubMed]
- Lin, M.W.; Su, K.Y.; Su, T.J.; Chang, C.C.; Lin, J.W.; Lee, Y.H.; Yu, S.L.; Chen, J.S.; Hsieh, M.S. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. Lung Cancer 2018, 125, 282–290. [Google Scholar] [CrossRef]
- Wu, S.G.; Chang, Y.L.; Yu, C.J.; Yang, P.C.; Shih, J.Y. The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition. Sci. Rep. 2016, 6, 35249. [Google Scholar] [CrossRef] [Green Version]
- Gow, C.H.; Liu, Y.N.; Li, H.Y.; Hsieh, M.S.; Chang, S.H.; Luo, S.C.; Tsai, T.H.; Chen, P.L.; Tsai, M.F.; Shih, J.Y. Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer. Neoplasia 2018, 20, 838–847. [Google Scholar] [CrossRef] [PubMed]
- Raghav, L.; Chang, Y.H.; Hsu, Y.C.; Li, Y.C.; Chen, C.Y.; Yang, T.Y.; Chen, K.C.; Hsu, K.H.; Tseng, J.S.; Chuang, C.Y.; et al. Landscape of Mitochondria Genome and Clinical Outcomes in Stage 1 Lung Adenocarcinoma. Cancers 2020, 12, 755. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsu, Y.L.; Hung, J.Y.; Lee, Y.L.; Chen, F.W.; Chang, K.F.; Chang, W.A.; Tsai, Y.M.; Chong, I.W.; Kuo, P.L. Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis. Oncotarget 2017, 8, 104831–104854. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuo, Y.H.; Lin, Z.Z.; Yang, Y.Y.; Shao, Y.Y.; Shau, W.Y.; Kuo, R.N.; Yang, J.C.; Lai, M.S. Survival of patients with small cell lung carcinoma in Taiwan. Oncology 2012, 82, 19–24. [Google Scholar] [CrossRef]
- Chiang, C.L.; Hsieh, W.T.; Tang, C.H.; Sheu, M.L.; Chen, Y.M. Treatment patterns and survival in patients with small cell lung cancer in Taiwan. J. Chin. Med. Assoc. 2021, 84, 772–777. [Google Scholar] [CrossRef]
- Agra, Y.; Pelayo, M.; Sacristan, M.; Sacristan, A.; Serra, C.; Bonfill, X. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst. Rev. 2003, 4, CD001990. [Google Scholar] [CrossRef]
- Horn, L.; Mansfield, A.S.; Szczesna, A.; Havel, L.; Krzakowski, M.; Hochmair, M.J.; Huemer, F.; Losonczy, G.; Johnson, M.L.; Nishio, M.; et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 379, 2220–2229. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.V.; Reck, M.; Mansfield, A.S.; Mok, T.; Scherpereel, A.; Reinmuth, N.; Garassino, M.C.; De Castro Carpeno, J.; Califano, R.; Nishio, M.; et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 619–630. [Google Scholar] [CrossRef] [PubMed]
- Paz-Ares, L.; Dvorkin, M.; Chen, Y.; Reinmuth, N.; Hotta, K.; Trukhin, D.; Statsenko, G.; Hochmair, M.J.; Ozguroglu, M.; Ji, J.H.; et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 2019, 394, 1929–1939. [Google Scholar] [CrossRef]
- Shiao, T.H.; Chang, Y.L.; Yu, C.J.; Chang, Y.C.; Hsu, Y.C.; Chang, S.H.; Shih, J.Y.; Yang, P.C. Epidermal growth factor receptor mutations in small cell lung cancer: A brief report. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2011, 6, 195–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hwang, C.C.; Hsieh, T.Y.; Yeh, K.Y.; Chen, T.P.; Hua, C.C.; Chang, L.C.; Chen, J.R. The rare epidermal growth factor receptor (EGFR) gene mutation in small cell lung carcinoma patients. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. 2022. [Google Scholar] [CrossRef]
- Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fulop, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [Google Scholar] [CrossRef] [Green Version]
- Gandhi, L.; Rodriguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [Google Scholar] [CrossRef]
- Peters, S.; Camidge, D.R.; Shaw, A.T.; Gadgeel, S.; Ahn, J.S.; Kim, D.W.; Ou, S.I.; Perol, M.; Dziadziuszko, R.; Rosell, R.; et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017, 377, 829–838. [Google Scholar] [CrossRef]
- Wu, Y.L.; Yang, J.C.; Kim, D.W.; Lu, S.; Zhou, J.; Seto, T.; Yang, J.J.; Yamamoto, N.; Ahn, M.J.; Takahashi, T.; et al. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2018, 36, 1405–1411. [Google Scholar] [CrossRef]
- Shaw, A.T.; Ou, S.H.; Bang, Y.J.; Camidge, D.R.; Solomon, B.J.; Salgia, R.; Riely, G.J.; Varella-Garcia, M.; Shapiro, G.I.; Costa, D.B.; et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014, 371, 1963–1971. [Google Scholar] [CrossRef] [Green Version]
- Planchard, D.; Smit, E.F.; Groen, H.J.M.; Mazieres, J.; Besse, B.; Helland, A.; Giannone, V.; D’Amelio, A.M., Jr.; Zhang, P.; Mookerjee, B.; et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: An open-label, phase 2 trial. Lancet Oncol. 2017, 18, 1307–1316. [Google Scholar] [CrossRef]
- Wolf, J.; Seto, T.; Han, J.Y.; Reguart, N.; Garon, E.B.; Groen, H.J.M.; Tan, D.S.W.; Hida, T.; de Jonge, M.; Orlov, S.V.; et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2020, 383, 944–957. [Google Scholar] [CrossRef]
- Paik, P.K.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A.B.; Garassino, M.C.; Mazieres, J.; Viteri, S.; Senellart, H.; Van Meerbeeck, J.; et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N. Engl. J. Med. 2020, 383, 931–943. [Google Scholar] [CrossRef] [PubMed]
- Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217. [Google Scholar] [CrossRef] [PubMed]
- Solomon, B.J.; Mok, T.; Kim, D.W.; Wu, Y.L.; Nakagawa, K.; Mekhail, T.; Felip, E.; Cappuzzo, F.; Paolini, J.; Usari, T.; et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371, 2167–2177. [Google Scholar] [CrossRef] [Green Version]
- Yamadori, T.; Ishii, Y.; Homma, S.; Morishima, Y.; Kurishima, K.; Itoh, K.; Yamamoto, M.; Minami, Y.; Noguchi, M.; Hizawa, N. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 2012, 31, 4768–4777. [Google Scholar] [CrossRef] [Green Version]
- Papaiahgari, S.; Zhang, Q.; Kleeberger, S.R.; Cho, H.-Y.; Reddy, S.P. Hyperoxia Stimulates an Nrf2-ARE Transcriptional Response via ROS-EGFR-PI3K-Akt/ERK MAP Kinase Signaling in Pulmonary Epithelial Cells. Antioxid. Redox Signal. 2006, 8, 43–52. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Luo, Y.-H.; Liang, K.-H.; Huang, H.-C.; Shen, C.-I.; Chiang, C.-L.; Wang, M.-L.; Chiou, S.-H.; Chen, Y.-M. State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. Int. J. Mol. Sci. 2022, 23, 7037. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23137037
Luo Y-H, Liang K-H, Huang H-C, Shen C-I, Chiang C-L, Wang M-L, Chiou S-H, Chen Y-M. State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. International Journal of Molecular Sciences. 2022; 23(13):7037. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23137037
Chicago/Turabian StyleLuo, Yung-Hung, Kung-Hao Liang, Hsu-Ching Huang, Chia-I Shen, Chi-Lu Chiang, Mong-Lien Wang, Shih-Hwa Chiou, and Yuh-Min Chen. 2022. "State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan" International Journal of Molecular Sciences 23, no. 13: 7037. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23137037